UroGen Pharma (URGN) Net Margin (2017 - 2026)
UroGen Pharma's (URGN) quarterly Net Margin came in at 46.26% in Q1 2026, up 17021.0% YoY from N/an in Q1 2025, and down 294.49% on a QoQ basis from 23.79% in Q4 2025.
UroGen Pharma (URGN) Net Margin (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of Net Margin data on file, last reported at 46.26% in Q1 2026.
- Quarterly Net Margin rose 17021.0% year-over-year to 46.26% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 69.66% (up 4689.0% YoY) and the FY2025 annual result came in at 107.6%, down 194.0% from the prior year.
- Net Margin eased to 46.26% in Q1 2026, from 23.79% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 23.79% in Q4 2025 to a low of 216.47% in Q1 2025.
- A 5-year average of 114.47% and a median of 121.34% in 2025 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2025 — Net Margin slumped 5335 bps — and 2026, when it jumped 17021 bps.
- Tracing URGN's Net Margin over 5 years: stood at 12.53% in 2022, then soared by 118 bps to 2.21% in 2023, then slumped by 1235 bps to 25.04% in 2024, then soared by 195 bps to 23.79% in 2025, then plunged by 294 bps to 46.26% in 2026.
- The last three Net Margin figures came in at 46.26% (Q1 2026), 23.79% (Q4 2025), and 121.34% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | -19.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.81% |
| Mar 31, 2026 | -46.26% |
| Dec 31, 2025 | 23.79% |
| Sep 30, 2025 | -121.34% |
| Jun 30, 2025 | -206.24% |
| Mar 31, 2025 | -216.47% |
| Dec 31, 2024 | -25.04% |
| Sep 30, 2024 | -93.93% |
| Jun 30, 2024 | -152.89% |
| Mar 31, 2024 | -171.91% |
| Dec 31, 2023 | 2.21% |
| Sep 30, 2023 | -104.93% |
| Jun 30, 2023 | -114.18% |
| Mar 31, 2023 | -175.74% |
| Dec 31, 2022 | -12.53% |
| Sep 30, 2022 | -160.47% |
| Jun 30, 2022 | -160.75% |
| Mar 31, 2022 | -209.32% |
| Dec 31, 2021 | -11.43% |
| Sep 30, 2021 | -266.15% |